The falsehoods and fearmongering could jeopardise the public response to a future pandemic, researchers warn. Read more at ...

The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...

Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.

A Peninsula biotech company focusing on a deadly lung-scarring disease lost more than half its stock value Monday after ...

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

For patients with advanced emphysema, EBV is associated with higher mortality and morbidity compared with LVRS.

Shares in Pliant Therapeutics plunged in after-hours trading after the US biotech revealed that it has paused a phase 2b/3 trial of its lead drug for idiopathic pulmonary fibrosis (IPF) after seeing a ...

FIBRONEER™-ILD was a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nerandomilast ...

The Flu, COVID-19, and RSV are all spiking at the same time, and have been "somewhat crippling" for healthcare providers the ...

The following is a summary of “Artificial Intelligence-Based Early Prediction of Acute Respiratory Failure in the Emergency ...